Lorus Therapeutics Inc. (LOR.TO, LRUSF.PK) announced that the Canadian Intellectual Property Office has issued the company's patent for its cancer immunotherapy agent, IL-17E.
According to Lorus, the Canadian patent protects the use of IL-17E to treat cancer, including many different solid tumors such as colon, breast, ovarian, pancreatic, and lung cancers as well as melanoma until 2026. In addition, the patent covers treatment of these cancers with IL-17E in combination with several approved anticancer therapeutics, including Avastin (bevacizumab), Gemzar (gemcitabine), Tarceva (erlotinib), Taxotere (docetaxel), Taxol (paclitaxel) and cisplatin.
For comments and feedback: editorial@rttnews.com